04232nam 2200637Ia 450 991083097930332120230721004755.01-118-67350-61-282-34938-497866123493860-470-74134-1(CKB)1000000000707370(EBL)416371(OCoLC)313862959(SSID)ssj0000112506(PQKBManifestationID)11129193(PQKBTitleCode)TC0000112506(PQKBWorkID)10097330(PQKB)11102822(MiAaPQ)EBC416371(EXLCZ)99100000000070737020080915d2008 uy 0engur|n|---|||||txtccrBiotechnology valuation[electronic resource] an introductory guide /Karl D. KeeganChichester, England ;Hoboken, NJ John Wiley & Sonsc20081 online resource (220 p.)Wiley financeDescription based upon print version of record.0-470-51178-8 Includes bibliographical references (p. [189]-192) and index.Biotechnology Valuation; Contents; Acknowledgements; 1 Introduction; Biotechnology Background; 2 Traditional Valuation Methods; The Value of a Company; Accounts - Providing the Data for Valuation Analysis; The Income Statement; Balance Sheet; Cash Flow Statement; Income Statement Multiples; Balance Sheet Multiples; Summary; Discounted Cash Flow Analysis; Net Present Value; Constructing the DCF; Projecting the Cash Flow Stream; Choosing a Discount Rate; Other Thoughts; 3 The Drug Development Process; The Drug Development Process; Drug Discovery and Research; Pre-Clinical DevelopmentClinical TrialsWhat Investors Should Look For When Analysing Clinical Trials; Conclusion; The Regulatory Process; Regulation in the US; Regulation in Europe; The Label; Timelines for Approval; Post Approval; Investment Lessons; Case Study #1; 4 Biotechnology Company Valuation; Data Collation; NPV of the Pipeline; Calculations; Sensitivity Analyses; DCF of Whole Company; EBIT DCF of Products; Comparables Valuation; NPVs are Additive; Using all the Tools Available to Reach a Valuation Conclusion; Market Models; Conclusion; Appendix 1; Example 1; Example 2; Example 3; Appendix 2Biosimilar Update5 Decision Trees and Real Options; Decision Trees; Discount Rate; Deriving Scenarios; Conclusion; Decision Tree Example; Real Options; Valuing Options; Estimation of the Input Variables; Conclusions; 6 Biotechnology Investing; Types of Healthcare Investment; Biotechnology Sector Evolution; Biotechnology Investment Cycles; Biotechnology Business Models; Focus on People; Cash; Product Pipeline; Commercial Risks; Newsflow; Lessons from Biotech Investing; 7 Early-stage Valuation; Private Valuation; Discounted Cash Flow Method; Comparable Valuation; Venture Capital MethodDiscount RatesConclusion; Glossary; References; IndexThe first book to provide a simple and practical means of valuing biotech companiesThe book begins with a short history of the biotechnology industry; this is important as although it is about 30 years old, the first company went public only in 1996, so it is possible to plot the course of investment waves and dipsIt examines the European industry and its evolvement, and draws parallels between the similarities and differences between that and the USLooks at the various companies which make up the biotech industry (therapeutic; life sciences; and the medical Wiley finance series.Biotechnology industriesValuationPharmaceutical industryValuationInvestment analysisBiotechnology industriesValuation.Pharmaceutical industryValuation.Investment analysis.332.63221380.1456606Keegan Karl D1683717MiAaPQMiAaPQMiAaPQBOOK9910830979303321Biotechnology valuation4054695UNINA